Successful Completion Of Russian GMP Inspection
CONCORDBIO · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Concord Biotech has successfully cleared the Russian GMP (Good Manufacturing Practice) inspection at its Active Pharmaceutical Ingredient (API) manufacturing facility in Dholka, Gujarat. The inspection was conducted over four days, from July 22 to July 25, 2025. Russian GMP certification is a key regulatory requirement that allows the company to manufacture and supply APIs to the Russian pharmaceutical market. The company highlighted this as a reflection of its commitment to global quality standards and regulatory compliance.
Positive for shareholders — this regulatory clearance strengthens Concord Biotech's ability to access and expand in the Russian market, potentially boosting export revenues and reinforcing its credibility with global regulatory authorities.